Cargando…

The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review

Background Revefenacin (REV) is a novel once-daily long-acting muscarinic antagonist (LAMA) in the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD). This systematic review incorporating a dose-response meta-analysis aimed to assess the efficacy and safety of REV. Met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jiaxing, Xie, Yihong, Kwong, Joey Sum-wing, Ge, Long, He, Rui, Zheng, Wenyi, Han, Jing, Zhang, Rui, Zhao, Huaye, He, Yuru, Li, Xiaosi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564370/ https://www.ncbi.nlm.nih.gov/pubmed/34744701 http://dx.doi.org/10.3389/fphar.2021.667027

Ejemplares similares

Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019
por: Zhang, Jiaxing, et al.
Publicado: (2020)

The Role of Revefenacin in Chronic Obstructive Pulmonary Disease
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

The Effectiveness of Clinical Pharmacist-Led Consultation in the Treatment of Infectious Diseases: A Prospective, Multicenter, Cohort Study
por: Zhang, Jiaxing, et al.
Publicado: (2020)

Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis
por: Zhang, Jiaxing, et al.
Publicado: (2019)

Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease
por: Lo, Arthur, et al.
Publicado: (2020)

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
por: Donohue, James, et al.
Publicado: (2019)

Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)

Correction to: Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2019)

The Clinical Pharmacist-Led Consultation for Infectious Diseases in Guizhou Province, China: A Survey Among Hospital Pharmacies
por: Zhang, Jiaxing, et al.
Publicado: (2020)

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
por: Donohue, James F., et al.
Publicado: (2019)

Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease
por: Hvisdas, Christopher
Publicado: (2021)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
por: Sethi, Sanjay, et al.
Publicado: (2020)

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
por: Pudi, Krishna K., et al.
Publicado: (2017)

Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis
por: Zhang, Jiaxing, et al.
Publicado: (2018)

Conbercept for patients with age-related macular degeneration: a systematic review
por: Zhang, Jiaxing, et al.
Publicado: (2018)

Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis
por: Zhang, Jiaxing, et al.
Publicado: (2018)

Progression of the PI3K/Akt signaling pathway in chronic obstructive pulmonary disease
por: Liu, Yanhui, et al.
Publicado: (2023)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Drug Safety of Benzodiazepines in Asian Patients With Chronic Obstructive Pulmonary Disease
por: Liao, Yi-Hsiang, et al.
Publicado: (2020)

Evaluation of a clinical pharmacist consultation service for patients with infectious diseases in China: a systematic review and meta-analysis
por: Zhang, Jiaxing, et al.
Publicado: (2020)

Risk for Cardiovascular Disease and One-Year Mortality in Patients With Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea Syndrome Overlap Syndrome
por: Tang, Manyun, et al.
Publicado: (2021)

Editorial: Drug Development and Target Discovery in Pulmonary Vascular Diseases
por: Zhang, Rui, et al.
Publicado: (2020)

Pharmacokinetics, metabolite profiling, safety, and tolerability of inhalation aerosol of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy Chinese subjects
por: Gao, Huaye, et al.
Publicado: (2022)

Imbalance of Endogenous Hydrogen Sulfide and Homocysteine in Chronic Obstructive Pulmonary Disease Combined with Cardiovascular Disease
por: He, Yanjing, et al.
Publicado: (2017)

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis
por: Shu, Tingting, et al.
Publicado: (2021)

Efficacy and safety of three species of Rhodiola L. in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
por: Yu, Haichuan, et al.
Publicado: (2023)

Pharmacological effects of Bufei Jianpi granule on chronic obstructive pulmonary disease and its metabolism in rats
por: Yang, Xin-Xin, et al.
Publicado: (2022)

Association between Antibiotic Exposure and the Risk of Rash in Children with Infectious Mononucleosis: a Multicenter, Retrospective Cohort Study
por: Zhang, Rui, et al.
Publicado: (2023)

Herb-symptom analysis of Erchen decoction combined with Xiebai powder formula and its mechanism in the treatment of chronic obstructive pulmonary disease
por: Ye, Hua, et al.
Publicado: (2023)

Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease
por: Chen, Chung-Yu, et al.
Publicado: (2021)

Role of Proteases in Chronic Obstructive Pulmonary Disease
por: Pandey, Kailash C., et al.
Publicado: (2017)

Evaluation of the Effectiveness of Clinical Pharmacists’ Consultation in the Treatment of Infectious Diseases: A Single-Arm, Prospective Cohort Study
por: Zhang, Jiaxing, et al.
Publicado: (2019)

Small airway dysfunction in idiopathic pulmonary fibrosis
por: Yin, Chengsheng, et al.
Publicado: (2022)

A Meta-Analysis of Folic Acid in Combination with Anti-Hypertension Drugs in Patients with Hypertension and Hyperhomocysteinemia
por: Wang, Wen-Wen, et al.
Publicado: (2017)

Potential Natural Small Molecular Compounds for the Treatment of Chronic Obstructive Pulmonary Disease: An Overview
por: Li, Liu-Ying, et al.
Publicado: (2022)

Induced Pluripotent Stem Cells Inhibit Bleomycin-Induced Pulmonary Fibrosis in Mice through Suppressing TGF-β1/Smad-Mediated Epithelial to Mesenchymal Transition
por: Zhou, Yan, et al.
Publicado: (2016)

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
por: Liu, Yu-Yang, et al.
Publicado: (2023)

Roles of autophagy-related genes in the therapeutic effects of Xuanfei Pingchuan capsules on chronic obstructive pulmonary disease based on transcriptome sequencing analysis
por: Zhang, Ye, et al.
Publicado: (2023)

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
por: Liu, Yu-Yang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lk5affecl8b908bdaauqn2f4db